Dr. Lanying Du, LFKRI's Co-Head of Viral Immunology Laboratory, has received her first NIH R01 grant on Middle East Respiratory Syndrome (MERS) coronavirus (MERS-CoV) vaccines. NIH’s division National Institute of Allergy and Infectious Diseases (NIAID) funds this program.

MERS-CoV, a newly emerging, highly pathogenic infectious virus, continues to threat public health worldwide with high mortality rate (about 35%). Currently, there are no MERS vaccines approved for use in humans. In this grant, Dr. Du and collaborators will rationally design safe and effective novel MERS-CoV vaccines, investigate their immunogenicity and mode of action, and evaluate their protective mechanisms against MERS-CoV infection.

This 5-year grant has total funds of $4.1 million, of which NYBC receives $2.2 million. Dr. Shibo Jiang, Member and Co-Head of Viral Immunology Laboratory, and Dr. Jiang Zhu, of The Scripps Research Institute, will be collaborators on this grant.​